...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

** BETonMACE Phase 3 Cardio Outcomes Trial for Apabetalone Has Reached its Targeted 250 MACE Events ** Top-Line Data Expected Mid-Year 2019 https://clinicaltrials.gov/ct2/show/NCT02586155

Free
AGORACOM NEWS FLASH

BREAKING: Spyder Cannabis Announces Plans to Enter US Hemp Derived Market Through Rollout of Boutique Retail and Kiosk Stores

  • Newly Listed Spyder Cannabis $SPDR.ca Announces Phase 1 plan for locations in 4 states
  • Already an established Ontario retail operator
  • Partnering with developers & realtors for prime real estate high traffic areas (Malls, Sport Venues)

Spdr logo large

Hub On AGORACOM / Read Release

Message: Low Impact Journals

One thing that is bothering me a lot as I research Resverlogix is the journals their research is published in is the bottom tier of journals; at least from 2017. See below.

Can anyone else comment on the quality of their research and researchers. TIA


The Journal Citation Reports (JCR) database tracks all impact factors for 12,061 journals.  0nly 213 journal titles, or 2% of the journals tracked by JCR, have a 2016 impact factor of 10 or higher.  The top 5% of journals have impact factors approximately equal to or greater than 6 (553 journals or 4.6% of the journals tracked by JCR).  Approximately two-thirds of the journals tracked by JCR have a 2016 impact factor equal to or greater than 1.


 


RVX PUBLISHED REASEARCH SINCE 20)17


1.Atherosclerosis/Impact factor 4.239

2. American Journal of Cardiovascular Drugs ..... Impact Factor 2.741;

3.  Kidney and Blood Pressure Research

 Current Impact Factor: 3.

4. Kidney International    Impact Factor is 3.357 ...

5. Molecular Pharamcology 2017 impact factor of 3.987.

6. Journal of Cardiovascular Translational Research/Impact factor 2.319

 

 

Share
New Message
Please login to post a reply